152 related articles for article (PubMed ID: 28786105)
21. Current status of chemoprevention of head and neck cancer.
Benner SE; Lippman SM; Hong WK
Oncology (Williston Park); 1992 Aug; 6(8):61-6; discussion 66-8, 71 passim. PubMed ID: 1386997
[TBL] [Abstract][Full Text] [Related]
22. Placebo-controlled trial of 13-cis-retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk: implications for chemoprevention of lung cancer.
Ayoub J; Jean-François R; Cormier Y; Meyer D; Ying Y; Major P; Desjardins C; Bradley WE
J Clin Oncol; 1999 Nov; 17(11):3546-52. PubMed ID: 10550153
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism.
Weisman RA; Christen R; Los G; Jones V; Kerber C; Seagren S; Glassmeyer S; Orloff LA; Wong W; Kirmani S; Howell S
Otolaryngol Head Neck Surg; 1998 May; 118(5):597-602. PubMed ID: 9591856
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial of supplemental beta-carotene to prevent second head and neck cancer.
Mayne ST; Cartmel B; Baum M; Shor-Posner G; Fallon BG; Briskin K; Bean J; Zheng T; Cooper D; Friedman C; Goodwin WJ
Cancer Res; 2001 Feb; 61(4):1457-63. PubMed ID: 11245451
[TBL] [Abstract][Full Text] [Related]
25. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
[TBL] [Abstract][Full Text] [Related]
26. Retinoid chemoprevention of second primary tumors.
Benner SE; Lippman SM; Hong WK
Semin Hematol; 1994 Oct; 31(4 Suppl 5):26-30. PubMed ID: 7831582
[TBL] [Abstract][Full Text] [Related]
27. Chemoprevention of head and neck cancer.
Voravud N
J Med Assoc Thai; 1996 Mar; 79(3):185-93. PubMed ID: 8708501
[TBL] [Abstract][Full Text] [Related]
28. The retinoic acid paradox in cancer chemoprevention.
Freemantle SJ; Dragnev KH; Dmitrovsky E
J Natl Cancer Inst; 2006 Apr; 98(7):426-7. PubMed ID: 16595769
[No Abstract] [Full Text] [Related]
29. Results, toxicity and compliance in chemoprevention trials of head and neck cancer.
Toma S; Palumbo R; Rosso R
Eur J Cancer Prev; 1994 Jan; 3(1):63-8. PubMed ID: 8130719
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies.
Do KA; Johnson MM; Lee JJ; Wu XF; Dong Q; Hong WK; Khuri FR; Spitz MR
Cancer; 2004 Dec; 101(12):2837-42. PubMed ID: 15536619
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of a placebo run-in period in a head and neck cancer chemoprevention trial.
Hudmon KS; Chamberlain RM; Frankowski RF
Control Clin Trials; 1997 Jun; 18(3):228-40. PubMed ID: 9204223
[TBL] [Abstract][Full Text] [Related]
32. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
Argiris A; Brockstein BE; Haraf DJ; Stenson KM; Mittal BB; Kies MS; Rosen FR; Jovanovic B; Vokes EE
Clin Cancer Res; 2004 Mar; 10(6):1956-62. PubMed ID: 15041712
[TBL] [Abstract][Full Text] [Related]
33. [Prevention of second primary cancer with vitamin supplementation in patients treated for head and neck cancers].
Bairati I; Brochet F; Roy J; Gélinas M; Nabid A; Têtu B; Mâsse B; Meyer F
Bull Cancer Radiother; 1996; 83(1):12-6. PubMed ID: 8679274
[TBL] [Abstract][Full Text] [Related]
34. Head and neck cancer associated with esophageal cancer.
Watanabe A; Hosokawa M; Taniguchi M; Tsujie H; Sasaki S
Auris Nasus Larynx; 2007 Jun; 34(2):207-11. PubMed ID: 17070004
[TBL] [Abstract][Full Text] [Related]
35. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer.
Rice D; Kim HW; Sabichi A; Lippman S; Lee JJ; Williams B; Vaporciyan A; Smythe WR; Swisher S; Walsh G; Putnam JB; Hong WK; Roth J
Ann Thorac Surg; 2003 Oct; 76(4):1001-7; discussion 1007-8. PubMed ID: 14529975
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis of second head and neck tumors in primary laryngeal SCC is an indicator of overall survival and not associated with poorer overall survival: a single centre study in 987 patients.
Farhadieh RD; Salardini A; Yang JL; Russell P; Smee R
J Surg Oncol; 2010 Jan; 101(1):72-7. PubMed ID: 19798688
[TBL] [Abstract][Full Text] [Related]
37. Second primary tumors in laryngeal cancer: results of long-term follow-up.
Narayana A; Vaughan AT; Fisher SG; Reddy SP
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):557-62. PubMed ID: 9806515
[TBL] [Abstract][Full Text] [Related]
38. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.
Motzer RJ; Schwartz L; Law TM; Murphy BA; Hoffman AD; Albino AP; Vlamis V; Nanus DM
J Clin Oncol; 1995 Aug; 13(8):1950-7. PubMed ID: 7636535
[TBL] [Abstract][Full Text] [Related]
39. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor-alpha: a surrogate endpoint biomarker?
Beenken SW; Hockett R; Grizzle W; Weiss HL; Pickens A; Perloff M; Malone WF; Bland KI
J Am Coll Surg; 2002 Aug; 195(2):149-58. PubMed ID: 12168960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
